Background: Patent ductus arteriosus is a congenital condition with high morbidity, especially in preterm infants of extremely low birth weight, representing 5% to 10% of congenital heart diseases. Our objective was to describe the approaches used at a reference hospital for the percutaneous occlusion of PDA. Methods: We conducted a retrospective study on the transcatheter treatment of patent ductus arteriosus from April of 2008 to April of 2010. Results: Forty-seven cases were reviewed and most of them (78.8%) were treated with Flipper™ coils while the remaining patients received the Amplatzer™ device. Ductal morphological configuration was Krichenko type A in 89.4% (34 in the Flipper™ coil group and 8 in the Amplatzer™ group), type D in 6.4% (2 in the Flipper™ coil group and 1 in the Amplatzer™ group) and type E in 4.2% (1 in each group) of patients. Pre-catheterization minimum diameters were 2.6 ± 0.8 mm and 3.8 ± 1.6 mm for the Flipper™ coil and Amplatzer™ groups, respectively. Immediate total occlusion of the defect was obtained in the control angiography in 72.3% of the patients. Seven patients treated with the Flipper™ coil received additional coils and two patients treated with the Amplatzer™ device presented minimal residual shunts. There were no procedure-related complications. In the follow-up after hospital discharge, one patient presented minimal residual shunt at the echography, 45 days after catheterization. Conclusions: Percutaneous patent ductus arteriosus occlusion has proven to be safe and effective in most cases.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.